Defunct Company
Total Trials
31
As Lead Sponsor
28
As Collaborator
3
Total Enrollment
4,888
NCT00123279
Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
Phase: Phase 2
Role: Lead Sponsor
Start: Dec 31, 2004
Completion: Nov 30, 2008
NCT00123292
Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
Start: Mar 31, 2005
Completion: Nov 30, 2009
NCT00123305
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
Start: Oct 31, 2005
Completion: Jun 30, 2008
NCT00123266
Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion
Start: Dec 31, 2006
Completion: Aug 31, 2008
NCT00412451
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
Completion: Mar 31, 2010
NCT00412958
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Completion: Oct 31, 2008
NCT00435539
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
Start: Feb 28, 2007
Completion: Feb 28, 2009
NCT00428129
Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT
Start: Mar 31, 2007
NCT00612196
A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers
Phase: Phase 1
Completion: Dec 31, 2007
NCT00612417
Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402
Start: Jan 31, 2008
NCT00618579
Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin
Start: Feb 29, 2008
NCT00781859
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
Phase: Phase 3
Start: Dec 31, 2008
Completion: Apr 30, 2010
NCT00793234
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
NCT00798317
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Completion: Jul 31, 2010
NCT00996684
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
Role: Collaborator
Start: Oct 31, 2009
Completion: Dec 31, 2011
NCT00913744
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Start: Jan 31, 2010
Completion: Apr 30, 2013
NCT01055535
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
Completion: Apr 30, 2011
NCT00986362
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
Start: Feb 28, 2010
Completion: Apr 30, 2012
NCT01159665
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
Start: Jul 31, 2010
Completion: Jan 31, 2011
NCT01344954
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
Start: Apr 30, 2011
Completion: May 31, 2012
NCT01287988
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
Phase: N/A
Start: May 31, 2011
Completion: Oct 31, 2011
NCT01429441
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Start: Oct 31, 2011
Completion: Oct 31, 2014
NCT02079883
Ocriplasmin Research to Better Inform Treatment (ORBIT)
Start: May 31, 2014
Completion: May 31, 2016
NCT02160340
Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older
Completion: May 31, 2017
NCT02193945
A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA
Start: Aug 31, 2014
Completion: May 31, 2015
NCT02681809
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Start: Dec 31, 2015
Completion: Nov 18, 2019
NCT03071068
A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
Start: Dec 22, 2016
Completion: Apr 30, 2018
NCT03511898
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
Start: May 18, 2018
Completion: May 22, 2019
NCT03666923
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
Start: Sep 17, 2018
Completion: Nov 20, 2019
NCT03669393
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
Start: Sep 18, 2018
Completion: Nov 22, 2019
NCT04300881
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)
Start: Oct 4, 2019
Completion: Jan 5, 2021